Abstract:Nowadays, effective immunotherapy against triple-negative breast cancer (TNBC) remains challenging due to the immunosuppressive tumor microenvironment. Immune checkpoint inhibitor is mostly employed to restore the activity of tumor-specific immune cells, which however brings little therapeutic outcome owing to the limited number of tumor-infiltrating CD8 + T cells and the inefficient delivery of immune drugs to the tumor tissue. Aiming to solve these problems, we herein constructed a tailor-made dissolving microneedle co-encapsulating the TLR7/8 agonist R848 and the immune checkpoint inhibitor aPD-1, termed αNP-RNP@DMN, and fabricated it as a transdermal drug delivery system. This well-designed microneedle patch, endowed with efficient tumor drug delivery ability, was able to mature tumor-infiltrating dendritic cells (TIDCs) and further promote the infiltration of CD8 + T cells into the tumor tissue with the aid of R848. Moreover, the introduction of aPD-1 blocked the programmed cell death protein 1/programmed cell death ligand 1(PD-1/PD-L1) immune checkpoints synergistically reversing the immunosuppressive microenvironment of TNBC. In vivo therapeutic results demonstrated that αNP-RNP@DMN not only significantly prolonged the survival time of 4T1 tumor-bearing mice, but also inhibited tumor recurrence and lung metastasis after surgery, implying the great potential of this effective drug delivery system for enhanced immunotherapy of superficial tumors. Statement of significance The limited number of tumor-infiltrating CD8 + T cells and the inefficient delivery of immune drugs to the tumor tissue hinder the effective immunotherapy of triple-negative breast cancer (TNBC). Herein, a dissolving microneedle co-encapsulating TLR7/8 agonist R848 and immune checkpoint inhibitor aPD-1 was developed and fabricated as a transdermal drug delivery system. This tailor-made microneedle patch not only promoted drug accumulation in tumor sites in a safe and painless manner, but also lifted the immune-suppressive state of tumor-infiltrating dendritic cells (TIDCs). The activated TIDCs further enhanced T-cell infiltration into the tumor tissue, thus successfully boosting the therapeutic efficacy of aPD-1. This study demonstrated that this well-designed microneedle patch could be served as an effective drug delivery system for enhanced immunotherapy of TNBC.

Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody.

Integrated Therapeutic Strategies for Various Cutaneous Malignancies: Advances and Challenges of Multifunctional Microneedle Patches Toward Clinical Translation

Rapidly Dissolving Microneedle Patch for Synergistic Gene and Photothermal Therapy of Subcutaneous Tumor

Dissolvable Self-Locking Microneedle Patches Integrated with Immunomodulators for Cancer Immunotherapy

Accelerated Cascade Melanoma Therapy using Enzyme-Nanozyme-Integrated Dissolvable Polymeric Microneedles

Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer

NIR Enhanced pH‐Responsive Microneedles for Synergetic Therapy of Melanoma

Double-layered microneedle patch loaded with bioinspired nano-vaccine for melanoma treatment and wound healing

A self-monitoring microneedle patch for light-controlled synergistic treatment of melanoma

A composite peptide-supramolecular microneedle system for melanoma immunotherapy

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Locoregional Melanoma Therapy by Tissue Adhesive Microneedle Patch-assisted Trans-tumoral Delivery of Anticancer Drug

A responsive microneedle system for efficient anti-melanoma by combining self-enhanced chemodynamic therapy with photothermal therapy

Correction to A Facile Low-Dose Photosensitizer-Incorporated Dissolving Microneedles-Based Composite System for Eliciting Antitumor Immunity and the Abscopal Effect.

Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma

Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy

Construction of microneedle-assisted co-delivery platform and its combining photodynamic/immunotherapy

Polymeric microneedles enable simultaneous delivery of cancer immunomodulatory drugs and detection of skin biomarkers

Photothermal Therapy Mediated by Phase-Transformation Nanoparticles Facilitates Delivery of Anti-Pd1 Antibody and Synergizes with Antitumor Immunotherapy for Melanoma

Microneedle-assisted vaccination combined with autophagy regulation for antitumor immunotherapy